Tyropaque

Tyropaque Uses, Dosage, Side Effects, Food Interaction and all others data.

Tyropaque is a radiocontrast agent used in cholecystography, the X-ray diagnosis of gallstones under the trade names include Bilopaque, Lumopaque, Tyropaque, and Bilopac. The molecule contains three heavy iodine atoms which obstruct X-rays in the same way as the calcium in bones, which results in a visible image .

Tyropanoate sodium, also known as sodium tyropanoate, is a radiocontrast agent used in cholecystography (X-ray imagining and diagnosis of gallstones). This molecule contains three heavy iodine atoms which obstruct X-rays to produce a visible image. After injection, it is rapidly excreted into the bile .

Tyropaque
Uses
Dosage
Side Effect
Precautions
Interactions
Uses during Pregnancy
Uses during Breastfeeding
Accute Overdose
Food Interaction
Half Life
Volume of Distribution
Clearance
Interaction With other Medicine
Contradiction
Storage

Trade Name	Tyropaque
Generic	Tyropanoic acid
Type
Formula	C₁₅H₁₈I₃NO₃
Weight	Average: 641.026 Monoisotopic: 640.84208
Protein binding	Less than 5 % .
Groups	Approved
Therapeutic Class
Manufacturer
Available Country
Last Updated:	September 19, 2023 at 7:00 am

Uses

For use in cholecystography (X-ray diagnosis/imaging of gallstones).

Toxicity

LD50 i.v. in mice: 720 mg/kg .

Since the introduction of iopanoic acid (Telepaque) in 1951, widespread clinical application has demonstrated that this medium represents an ideal cholecystographic agent.1 Iopanoic acid [β-(3-amino-2, 4, 6-triiodophenyl)-α-ethylpropionic acid] contains 66.68% iodine. Maximum concentration in the gallbladder occurs at from 10 to 12 hours. Iopanoic acid is excreted primarily through the intestinal tract. Its elimination is rapid and complete within 48 hours. Toxic reactions to this agent are rare, and side-effects rarely occur .

Although the foregoing oral cholecystographic agents are relatively non-toxic substances, adverse reactions such as minor gastrointestinal disturbances or allergic reactions are occasionally observed. Therefore, it is highly desirable, in order to minimize the occurrence of these undesirable side-effects, to use as low a dose as possible and maintain the blood plasma iodine concentration at the lowest possible level without sacrificing adequate imaging of the gallbladder .

A study was done on this agent in basic form and slow-release form . The acute oral toxicity in mice of the basic formulation was determined, and a 7-day LD50 value of 5042 (3623-6596) mg/kg in terms of sodium tyropanoate was obtained. This compared to a Ld50 value of 3158 (1302-3900) for commercial sodium tyropanoate capsule mix (uncoated). The sustained release preparation was thus statistically significantly less toxic than the immediate-release material .

Elimination Route

This triiodide is well absorbed by the small intestine and it is excreted in the bile within 2 h after oral administration . It has been found to be readily absorbed and show maximal radiographic definition at 10-12 h post ingestion, but this can occur as early as 4-6h .